118 related articles for article (PubMed ID: 6254682)
1. Phase I clinical studies with WR-2721.
Kligerman MM; Shaw MT; Slavik M; Yuhas JM
Cancer Clin Trials; 1980; 3(3):217-21. PubMed ID: 6254682
[TBL] [Abstract][Full Text] [Related]
2. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
Milas L; McBride WH; Hunter N; Ito H
Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
[TBL] [Abstract][Full Text] [Related]
3. Rationale for initial clinical trials and future development of radioprotectors.
Phillips TL
Cancer Clin Trials; 1980; 3(2):165-73. PubMed ID: 6253097
[TBL] [Abstract][Full Text] [Related]
4. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of WR-2721 administered in single and multiple doses.
Kligerman MM; Glover DJ; Turrisi AT; Norfleet AL; Yuhas JM; Coia LR; Simone C; Glick JH; Goodman RL
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1773-6. PubMed ID: 6090369
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.
Milas L; Hunter N; Reid BO; Thames HD
Cancer Res; 1982 May; 42(5):1888-97. PubMed ID: 6279288
[TBL] [Abstract][Full Text] [Related]
7. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].
Turrisi AT; Glover DJ; Hurwitz S; Glick J; Norfleet AL; Weiler C; Yuhas JM; Kligerman MM
Cancer Treat Rep; 1986 Dec; 70(12):1389-93. PubMed ID: 2431774
[TBL] [Abstract][Full Text] [Related]
8. [Investigations with beagles about toxicity and radioprotective effect of the clinical radioprotection substance WR 2721. Part I. Toxicity of WR 2721 (author's transl)].
Wagner M; Sedlmeier H; Wustrow T; Messerschmidt O
Strahlentherapie; 1980 Jul; 156(7):486-91. PubMed ID: 6258271
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effects of WR-2721 on mouse testicular cells.
Meistrich ML; Finch MV; Hunter N; Milas L
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1551-4. PubMed ID: 6090360
[TBL] [Abstract][Full Text] [Related]
10. Frequency of micronuclei in mouse peripheral blood erythrocytes following WR-2721 application and X-irradiation.
Mazur L
Folia Biol (Krakow); 1995; 43(3-4):111-4. PubMed ID: 8782430
[TBL] [Abstract][Full Text] [Related]
11. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
12. Effect of WR-2721 on fetal development in the rat.
Sodicoff M; Ziskin MC; Conger AD
Radiat Res; 1986 Jul; 107(1):49-57. PubMed ID: 3016791
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine.
Fleischer G; Dörr W
Strahlenther Onkol; 2006 Oct; 182(10):567-75. PubMed ID: 17013569
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
16. Radiation protection of rat parenchymal hepatocytes with S-2-(3-aminopropylamino)ethylphosphorothioic acid.
Jirtle RL; Pierce LJ; Crocker IR; Strom SC
Radiother Oncol; 1985 Nov; 4(3):231-7. PubMed ID: 3001838
[TBL] [Abstract][Full Text] [Related]
17. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
18. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
19. Suppression of delayed-type hypersensitivity to oxazolone in whole-body-irradiated mice and protection by WR-2721.
Srinivasan V; Weiss JF
Radiat Res; 1984 Jun; 98(3):438-44. PubMed ID: 6328568
[TBL] [Abstract][Full Text] [Related]
20. Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration.
Mangold DJ; Miller MA; Huelle BK; Sanchez-Barona DO; Swynnerton NF; Fleckenstein L; Ludden TM
Drug Metab Dispos; 1989; 17(3):304-10. PubMed ID: 2568913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
